Nuvalent Inc.

2 months ago · gurufocus.com

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propo

3 months ago · globenewswire.com

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc.

3 months ago · globenewswire.com

BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

3 months ago · globenewswire.com

MONSEY, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Nuvalent, Inc. (Nasdaq: NUVL) (“NUVL”) for $124.00 per share in cash to GSK in a tender offer.

4 months ago · globenewswire.com

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation.

4 months ago · benzinga.com

U.S. stocks were higher, with the Dow Jones index gaining over 300 points on Tuesday.

4 months ago · investors.com

Nuvalent shares catapulted to a record high Tuesday after GSK made an all-cash bid to buy the small biotech company for $10.6 billion.

4 months ago · schaeffersresearch.com

Nuvalent Inc (NASDAQ:NUVL) is soaring in premarket trading, up 38.9% to trade at $122.88, after London-based GSK agreed to acquire the cancer drug developer in an all-cash deal valued at approximately $10.6 billion.

4 months ago · businesswire.com

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Nuvalent, Inc. (NASDAQ: NUVL) to GSK plc for $124.00 per share in cash. Halper Sadeh encourages Nuvalent shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Nuvalent and its board of directors violated the federal.

4 months ago · proactiveinvestors.com

GSK PLC (LSE:GSK, NYSE:GSK) shares fell 3% after it agreed to acquire US biotechnology company Nuvalent (NASDAQ:NUVL) for $10.6 billion (£8.0 billion),...